Edwards Lifesciences is expected to report fiscal second-quarter 2026 results soon, with analysts forecasting an adjusted EPS of $0.73, up nearly 9% from $0.67 a year ago. The company has beaten Wall Street's bottom-line estimates in three of the past four quarters. For the full fiscal year 2026, analysts project adjusted EPS of $3, a 17.2% increase from $2.56 in fiscal 2025. Following its first-quarter results, shares rose 5.6% as sales grew 16.7% to $1.65 billion, driven by a 14.4% increase in TAVR sales to $1.20 billion and TMTT sales of $173 million, while the company raised its full-year guidance. Analysts have a consensus 'Moderate Buy' rating on the stock with an average price target of $97.48, implying a potential upside of 6.9%.
Edwards Lifesciences CorpAnalysts forecast higher EPS and strong sales growth, with raised guidance and positive analyst rating
Advanced Micro Devices Inc